THERALASE TECH INC (OTCMKTS:TLTFF)
THERALASE TECH INC (OTCMKTS:TLTFF) fell 48.6% after reporting mixed trial results on a Phase 1b Non-Muscle Invasive Bladder Cancer clinical study, of TLD-1433. The sell-off pushed the stock to this year’s lows, consequently bringing to an end a bullish run that had pushed the stock to a 52-week high of $0.43.
TLD-1433 Preliminary Trial Results
Preliminary trial results indicate that the first three patients treated with the Maximum Recommended Starting Dose (MRSD) achieved primary and secondary outcome measures after 90 days of treatment. However, the three patients did not achieve the exploratory outcome measure at 180 days post-treatment.
The fourth patient’s bladder surface wall was observed to be red and inflamed at 90 days of post-treatment. The interim data suggest that Theralase PDT treatment was able to achieve primary and secondary objectives at both MRSD and Therapeutic Dose.
Enrollment and treatment of five additional patients should provide additional data, needed to further verify the ability of the treatment to achieve primary secondary and exploratory objectives. The interim data also supports that Photo Dynamic Therapy treatment at MRSD is very safe and tolerable for NMIBC patients.
Review of the data set should help in the determination of the optimal dose for initial or additional PDT treatments as required.
“Optimization of the dose of TLD-1433 to use in a Phase II clinical study, coupled with optimization of both the TLC-3200 and TLC-3400 DFOC technology, currently underway by the Company, to increase ease of manufacture and optimize uniformity of light distribution, will be important to successfully achieve a primary efficacy outcome measure,” said CEO Roger Dumoulin-White.
TLD-1433 For GBM Treatment
In addition to the clinical trials, THERALASE TECH INC (OTCMKTS:TLTFF) has patented the lead anti-cancer drug. TLD-1433 has already demonstrated to be effective in the destruction of human Glioblastoma Multiforme GBM cancer cells when activated by X-ray.
GBM are tumors that arise from astrocytes that make up or support the tissue of the brain. The condition represents 14.9% of all primary brain tumors and could affect 80,000 new people this year in the U.S alone
According to Dr. Pavel Kaspler, latest research data suggests that TLD-1433 has the potential to be effective in the destruction of GBM cells with a high safety margin
“This latest research confirms that the Company is on the right track to provide support for the design and commencement of a Phase Ib clinical study for patients inflicted with this deadly disease,” said Mr. Dumoulin-White.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $TLTFF and receive breaking news on other hot stocks by signing up for our free newsletter!